Trial Profile
A phase IV, randomized, open-label, multi-center study in adults: Evaluation of long-term immunogenicity in subjects boosted with a new TBE vaccine for adults (free of protein-derived stabilizer) in study V48P2E1, 5 years after first booster immunization and Evaluation of booster kinetics in subjects boosted with a new TBE vaccine for adults (free of protein-derived stabilizer), 5 years after first booster immunization.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2011
Price :
$35
*
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis virus infections
- Focus Pharmacodynamics
- Sponsors Chiron Behring
- 01 Jun 2011 New trial record